Triple-negative breast cancer

Triple-negative breast cancer (TNBC) lacks estrogen and progesterone receptors and HER2; with few effective therapies beyond chemotherapy, it is the breast cancer subtype with the least favorable outcomes (Bianchini et al., Nat Rev Clin Oncol 2022).
In this portal you'll find an overview of the disease, market maps, and maps of the ecosystem around it.

Triple-negative breast cancer (TNBC) at a glance: 344 active TNBC programs; 333 discontinued TNBC programs; 383 companies that have owned a TNBC program; 242 private investors in companies with TNBC programs; 40 of the 50 largest pharma companies with TNBC activity; 29 opportunities from foundations and funders: funding, data and samples, partnering support and events.Triple-negative breast cancer (TNBC) at a glance: 344 active TNBC programs; 333 discontinued TNBC programs; 383 companies that have owned a TNBC program; 242 private investors in companies with TNBC programs; 40 of the 50 largest pharma companies with TNBC activity; 29 opportunities from foundations and funders: funding, data and samples, partnering support and events.

Market maps

Ecosystem